US › Healthcare

Tenax Therapeutics Inc (TENX)

US · Healthcare · Biotechnology

$1.86+2.20%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-17.8M

EPS

$-0.35

EPS estimate

$-0.38

EPS came in at -0.35 against a street estimate of -0.38 — a beat of 7.9%.

Key statistics

Market cap

$69.6M

Forward P/E

0.3

P/B

0.61

Book value

$2.29

EPS (TTM)

$-1.48

52-week high

$19.40

52-week low

$1.31

50-day MA

$8.89

200-day MA

$11.77

Beta

0.82

Analyst view

Analysts rate Tenax Therapeutics Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $12.56.

Shareholding

Insiders

0.11%

Institutions

117.48%

Largest institutional holders

Fund	Stake
T. Rowe Price Associates, Inc.	7.89%
Vivo Capital, LLC	6.68%
HHG PLC	4.85%
Perceptive Advisors LLC	4.54%
VR Adviser, LLC	4.48%
Ikarian Capital, LLC	2.72%
Stonepine Capital Management Llc	2.61%
Millennium Management LLC	2.34%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tenax Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.